Lee Yuchun's Form 4 filing
Vertex Pharmaceuticals Inc (VRTX) · filed Jan 25, 2023
- Accession no.
- 0001209191-23-004816
- Filed
- Jan 25, 2023
- Trade date
- Jan 23-24, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 5 non-derivative transactions and 2 derivative transactions. Open-market sales total $1.92M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lee YuchunCIK 0001334365 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 23, 2023 | Common Stock | MOption exerciseAcquired | +2,129 | $72.14 | +$153,586.06 | 4,004 | Direct | |
| Jan 23, 2023 | Common Stock | SSaleDisposed | −2,129 | $312.02F2,F3 | −$664,290.58 | 1,875 | Direct | |
| Jan 24, 2023 | Common Stock | MOption exerciseAcquired | +4,000 | $72.14 | +$288,560 | 5,875 | Direct | |
| Jan 24, 2023 | Common Stock | SSaleDisposed | −2,511 | $312.29F2,F4 | −$784,160.19 | 3,364 | Direct | |
| Jan 24, 2023 | Common Stock | SSaleDisposed | −1,489 | $313.36F2,F5 | −$466,593.04 | 1,875 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 23, 2023 | Common Stock | MOption exerciseDisposed | −2,129 | $0.00 | $0 | 13,429 | Direct | |
| Jan 24, 2023 | Common Stock | MOption exerciseDisposed | −4,000 | $0.00 | $0 | 9,429 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Referenced by the price of 3 transactions in Table I.
- F3
Open market sales reported on this line occurred at a weighted average price of $312.02 (range $312.00 to $312.17).
Referenced by the price of 1 transaction in Table I.
- F4
Open market sales reported on this line occurred at a weighted average price of $312.29 (range $312.00 to $312.92).
Referenced by the price of 1 transaction in Table I.
- F5
Open market sales reported on this line occurred at a weighted average price of $313.36 (range $313.00 to $313.73).
Referenced by the price of 1 transaction in Table I.